Loading...
OTCM
SPHDF
Market cap275mUSD
Apr 28, Last price  
23.25USD
Name

Santhera Pharmaceuticals Holding AG

Chart & performance

D1W1MN
OTCM:SPHDF chart
P/E
—
P/S
3.80
EPS
—
Vol. 1Y
—
Shs. 5Y
57.77%
Rev. 5Y
38.75%
Div Yld LY
—
Div Yld TTM
—
Revenues
77m
+97.32%
781,0009,226,00048,0001,643,00020,609,0003,265,0003,538,0001,319,0002,591,0004,321,00019,033,00022,943,00031,657,00075,376,00015,008,000-1,595,0007,473,000103,414,00039,117,00077,185,000
Net income
-49m
L+17.30%
-28,258,000-27,871,000-44,656,00025,923,000-11,256,000-27,838,000-31,448,000-5,755,000-7,534,0005,949,000-35,415,000-51,532,000-54,186,000-18,973,000-67,659,000-55,526,000-71,076,00054,782,000-41,974,000-49,236,000
CFO
-35m
L-2.15%
-24,833,000-22,371,000-45,691,000-20,753,000-6,636,000-19,894,000-11,039,000-6,976,000-6,063,000-22,390,000-27,137,000-39,633,000-37,865,0002,595,000-43,510,000-37,359,000-29,843,00047,271,000-35,527,000-34,763,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Related entities

Subsidiaries
SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD

Key people

Thomas Meier
Non-Executive Independent Chairman of the Board · since 2024
Dario Eklund
Chief Executive Officer, Member of the Executive Management Board · since 2023
Guenther Metz
Executive Vice President - Head Business Development, Member of the Executive Management Board · since 2019
Marc Schrader
Chief Technology Officer · since 2024
Geert- Jan van Daal
Chief Commercial Officer · since 2024
Shabir Hasham
Chief Medical Officer and Member of the Executive Management Board · since 2022
Oliver Kronenberg
Chief Legal Officer, Corporate Secretary, Member of the Executive Management Board · since 2024
Catherine Isted
Chief Financial Officer, Member of the Executive Management Board · since 2025
Melanie Rolli
Director · since 2025
Philipp Gutzwiller
Non-Executive Independent Director · since 2017
Bradley Meyer
Non-Executive Independent Director · since 2023
URL
https://www.santhera.com/
IPO date
Nov 03, 2006
Employees
45
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
HOHENRAINSTRASSE 24
PRATTELN, BL 4133
CH
Previous name
MyoContract AG
Previous name
MyoContract Pharmaceutical Research AG
Previous name
Santhera Pharmaceuticals AG

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT